Ballas SK - Search Results

1

Risk factors associated with increased emergency department utilization in patients with sickle cell disease: a systematic literature review.

Ballas SK, Dampier C. Ballas SK, et al. Ann Hematol. 2020 Nov;99(11):2483-2495. doi: 10.1007/s00277-020-04205-0. Epub 2020 Aug 27. Ann Hematol. 2020. PMID: 32852615

2

Dampier C, LeBeau P, Rhee S, Lieff S, Kesler K, Ballas S, Rogers Z, Wang W; Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC) Site Investigators. Dampier C, et al. Am J Hematol. 2011 Feb;86(2):203-5. doi: 10.1002/ajh.21905. Am J Hematol. 2011. PMID: 21264908 Free PMC article.

3

Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, Wang WC, Hoppe C, Hagar W, Darbari DS, Malik P. Ballas SK, et al. ScientificWorldJournal. 2012;2012:949535. doi: 10.1100/2012/949535. Epub 2012 Aug 1. ScientificWorldJournal. 2012. PMID: 22924029 Free PMC article. Review.

4

Opioid utilization patterns in United States individuals with sickle cell disease.

Ballas SK, Kanter J, Agodoa I, Howard R, Wade S, Noxon V, Dampier C. Ballas SK, et al. Am J Hematol. 2018 Oct;93(10):E345-E347. doi: 10.1002/ajh.25233. Epub 2018 Aug 21. Am J Hematol. 2018. PMID: 30051929 Free article. No abstract available.

5

AAAPT Diagnostic Criteria for Acute Sickle Cell Disease Pain.

Field JJ, Ballas SK, Campbell CM, Crosby LE, Dampier C, Darbari DS, McClish DK, Smith WR, Zempsky WT. Field JJ, et al. Among authors: ballas sk. J Pain. 2019 Jul;20(7):746-759. doi: 10.1016/j.jpain.2018.12.003. Epub 2018 Dec 19. J Pain. 2019. PMID: 30578848

6

Definitions of the phenotypic manifestations of sickle cell disease.

Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, Johnson CS, Rogers ZR, Smith-Whitley K, Wang WC, Telen MJ; Investigators, Comprehensive Sickle Cell Centers. Ballas SK, et al. Am J Hematol. 2010 Jan;85(1):6-13. doi: 10.1002/ajh.21550. Am J Hematol. 2010. PMID: 19902523 Free PMC article.

7

Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W; Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC). Dampier C, et al. Pediatr Blood Cancer. 2010 Sep;55(3):485-94. doi: 10.1002/pbc.22497. Pediatr Blood Cancer. 2010. PMID: 20658620 Free PMC article.

8

Opioids are not a major cause of death of patients with sickle cell disease.

Ballas SK. Ballas SK. Ann Hematol. 2021 May;100(5):1133-1138. doi: 10.1007/s00277-021-04502-2. Epub 2021 Mar 23. Ann Hematol. 2021. PMID: 33758998

9

The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.

Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM. Ballas SK, et al. Am J Hematol. 2018 Jul;93(7):943-952. doi: 10.1002/ajh.25103. Epub 2018 Apr 28. Am J Hematol. 2018. PMID: 29635754 Free article.

10

Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes.

Zeidan AM, Giri S, DeVeaux M, Ballas SK, Duong VH. Zeidan AM, et al. Among authors: ballas sk. Ann Hematol. 2019 Feb;98(2):339-350. doi: 10.1007/s00277-018-3539-7. Epub 2018 Nov 9. Ann Hematol. 2019. PMID: 30413901

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

338 results

Search Page